Page 13 - Hal Barron News Today

LONDON, Dec 7 — British drugmaker GSK said today its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies. The data, yet to be published in a peer-reviewed medical...

 – New preclinical findings generated through in vitro testing of sotrovimab againstthe complete pseudo-virus updated to bioRxiv – Data build on promising signal published... | December 7, 2021

The data, yet to be published in a peer-reviewed medical journal, shows the treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK says

07.12.2021 -  – New preclinical findings generated through in vitro testing of sotrovimab againstthe complete pseudo-virus updated to bioRxiv – Data build on promising signal published last week, underscoring the importance of sotrovimab for early treatment of ...

British drugmaker GSK said on Tuesday its antibody based COVID 19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of th...

New data shows GSK-Vir drug works against all omicron mutations

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.

GlaxoSmithKline on Tuesday said that its COVID-19 antibody treatment had positive results in lab tests that show it has the potential to be effective against the new omicron variant.

British drugmaker GlaxoSmithKline said early-stage lab data shows its COVID-19 monoclonal antibody treatment, jointly developed with U.S. partner Vir Biotechnology, is effective against all mutations of the new Omicron strain.

Data is yet to be published in a medical journal or scrutinized by other experts in a peer-review.